Prof. Majed Al Jeraisy obtained his Bachelor degree in Pharmaceutical science and Master of Science in Clinical Pharmacy from King Saud University, Riyadh in 1991 and 1996 respectively. He then obtained his Doctor of Pharmacy degree in 1999 from the University of Tennessee, USA, followed by two years of residency and fellowship in pediatric pharmacotherapy from the same place. Dr. Al Jeraisy has also completed a Master of Science degree in Medical Education from King Saud ben Abdulaziz University for Health Sciences, Riyadh in 2009.

Dr. Al Jeraisy is an Associate Professor of Pharmacy Practice, College of Pharmacy, King Saud Ben Abdulaziz University for Health Sciences and Pediatric Clinical Pharmacy Consultant in King Abdullah Specialized Children Hospital.

He was appointed as the chairman of research office at KAIMRC in 2007 and recently was appointed as the Director of Clinical Trial Services in 2018. Dr. Al Jeraisy is a reviewer of local and international peer reviewed journals, also he has authored and co-authored numerous and relevant scientific research projects in the field of Pediatrics, Pharmacotherapy, General Medicine, Biochemistry, Pharmacology and Toxicology that were published in reputable Journals.

Dr. Abdulrhman Aljouie is a Research Scientist at King Abdullah International Medical Research Center and Assistant Professor of Computer Science (joint appointment) at King Saud bin Abdulaziz University for Health Sciences. Dr. Aljouie’s research interest lie in the area of Medical Artificial Intelligence, including the development of multimodal deep learning networks for disease risk prediction using genomic and imaging data.  His work in machine learning has been published in top peer-reviewed journals. Dr. Aljouie holds a M.Sc. in Bioinformatics and a Ph.D. in Computer Science from New Jersey Institute of Technology, Newark, NJ, USA.

Dr. Waleed Alhazzani is a preeminent figure in medicine, serving as an associate professor at McMaster University and an honorary professor at King Saud University. As the CEO of the Scientific Research Center at MODHS in Riyadh, he leads pivotal international multicenter clinical trials. Notably, Dr. Alhazzani has authored over 220 publications and is a driving force in the creation of clinical practice guidelines on a global scale. He chairs the Guidelines in Intensive Care, Development, and Evaluation (GUIDE) group and has been instrumental in the development of the internationally recognized Surviving Sepsis Campaign guidelines. His contributions have been key to advancing evidence-based practices in critical care.

Dr. Al-Jazairi is a Clinical Pharmacy Consultant in the field of Cardiovascular Pharmacotherapy and the Director, Clinical Trials Transformation Division at the prestigious King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh Saudi Arabia. He received his Doctor of Pharmacy degree from Campbell University at Buies Creek, North Carolina, USA, and a general Pharmacy Practice Residency at Duke University Medical Center (DUMC), Durham, NC. In 2000, Dr. Al-Jazairi completed a two-year Specialty Residency in Cardiovascular Pharmacotherapy from Philadelphia College of Pharmacy (PCP), University of the Sciences in Philadelphia in conjunction with the Hospital University of Pennsylvania (HUP), Philadelphia, Pennsylvania. More recently, 2014, Dr. Al-Jazairi earned a Master degree in Pharmaceutical and Healthcare Business from Mayes College, University of the Sciences in Philadelphia. Dr. Al-Jazairi is a board certified pharmacotherapy specialist with Cardiology added-qualification.
Dr. Al-Jazairi has more than 50 original research publications, and delivered many national and international presentations. Dr. Al-Jazairi is the Founder of the Saudi Clinical Pharmacy Society, 2018. He is an editorial board member of prime journals, including Annals of Pharmacotherapy and the Annals of Saudi Medicine, for more than 15 years. He sets in several committees in Saudi-FDA, Saudi Commission for Health Specialties and Saudi Health Council. He is a member of the International Accreditation Commission, ASHP. Dr. Al-Jazairi enjoys training students and residents in Cardiology, Clinical Research and Evidence-based Medicine. Dr. Al-Jazairi is the Director of the first and only Cardiology Residency Program accredited by ASHP outside the States, at King Faisal Specialist Hospital and Research Center (KFSH&RC). He also serves as an Associate Professor, School of Pharmacy and School of Medicine in Alfaisal University, Qassim University, and adjunct Assistant Professor in Princess Nora University and member of the Advisory Board for College of Pharmacy.

Dr. Mohamed Al Jamaan, a Consultant in Preventive Medicine specializing in Epidemiology & Biostatistics, holds pivotal roles at KAH, MNGHA, and KAIMRC, KSAU-HS. He leads research at KAIMRC-ER and directs NGHA HS-PHC. With an M.B.B.S from King Faisal University and Saudi board certification in Community Medicine (Epidemiology), he has extensive experience in clinical preventive medicine and advanced data analysis. Dr. AlJamaan’s dedication to scientific progress is evident through his 14 publications and numerous research contributions.

Dr. Hisham Badreldin is a distinguished professional with a multifaceted career encompassing leadership, academia, clinical practice, and research in the fields of cardiovascular pharmacotherapy and health outcomes. Dr. Badreldin currently serve as the Director of the Saudi Biobank at KAIMRC, Riyadh, and an Associate Professor of Cardiovascular Pharmacotherapy at KSAU-HS. He has many leaderships on national and international platforms. Dr. Badreldin has received numerous honors and awards, including the Fellowship of the American College of Cardiology (FACC), Faculty Excellence in Clinical Practice Award from KSAU-HS, Fellowship of the American College of Chest Physicians (FCCP), and the Cardiology Clinical Practice, Leadership, Teaching, and Research International Award from the American College of Clinical Pharmacy (ACCP). His exemplary contributions underscore his commitment to improving patient outcomes, promoting education, and contributing to the global landscape of healthcare innovation.

Dr. Kanan Alshammari is a consultant of adult medical oncology at King Abdulaziz Medical City – Ministry of National Guard for Health Affairs (MNGHA) in Riyadh, Saudi Arabia, and an Assistant Professor at the College of Medicine of King Saud bin Abdulaziz University (KSAU) for Health Sciences. He is also the director of the NCCN MENA regional coordinating center at MNGHA. He finished his undergraduate training at the University of Otago in New Zealand obtaining his MBChB in 2008. He then obtained the Saudi Board of Internal Medicine in 2014. He did his medical oncology training at McMaster University in Hamilton, Canada, and obtained the Royal College of Physicians and Surgeons of Canada Subspecialty Affiliate certification in 2018. He then did another fellowship in drug development/phase 1 oncology trials and sarcoma in 2019 at the Princess Margaret Cancer Center in Toronto, Canada. He published in the areas of HCC, precision oncology, and has a great interest in sarcoma.

Dr. Maha AL Ammari is an accomplished Clinical Pharmacist at King Abdulaziz Medical City in Riyadh, Saudi Arabia with an over her 33-year career, she has held leadership roles, in Medication safety, research, patient education and others. Dr. Al Ammari has an impressive research record with over 20 papers published and presentations at national and international conferences. She actively participates in professional organizations, including the Saudi Council for Health Specialties and the Counsel Health Insurance in Saudi Arabia. Dr. Al Ammari’s dedication and contributions have significantly advanced the field of pharmacy in Saudi Arabia.

Dr. Bisher Abuyassin is a seasoned professional with a diverse background spanning nearly two decades, seamlessly bridging the realms of clinical pharmacy and basic science research. Throughout his career, Dr. Abuyassin has demonstrated a deep commitment to advancing medical knowledge by publishing numerous peer-reviewed articles and promoting ethical standards in research. Currently serving as a scientist at the Experimental Medicine Department at King Abdullah International Medical Research Center (KAIMRC), in addition to his role as the esteemed Chairman of the Bioethics Department. His wide clinical and experimental experience allowed for his nomination to be member of both, Institutional Review Board (IRB) and Institutional Animal Care & Use Committee (IACUC) of the Ministry of National Guard-Health Affairs.

Dr. Ibrahim Alsubaihi Experienced Clinical Trials Expert with a demonstrated history of working in the biotech industry such as Scottsdale healthcare center, Eli Lilly, Medtronic and government, such as SFDA, KFMC. Skilled in strategies, policy, Medical Affairs, and Clinical Trials. Physician with Strong research professional and master’s degree focused on clinical trials & Health Ethics from Arizona State University. Currently, he is the director of CTs Support and Development at Saudi NIH”

Dr. Mohammad Bosaeed, is a Consultant of Infectious Diseases, Deputy Chief of Medical Eligibility KAMC-RD, MNGHA, Chairman of Infectious Diseases Research Department at KAIMRC, Director of Clinical Efficiency, Clinical Strategy Department, MNGHA, and Assistant Professor in college of Medicine, KSAU-HS, Riyadh. Dr. Bosaeed has several peer-reviewed publications in international journals and has led multiple clinical trials in the infectious diseases field.

Dr. Asma Abdullah Alfayez is a postdoctoral researcher at KAIMRC, specialises in Artificial Intelligence (AI) and Big Data Sciences. She obtained her PhD from University College London (UCL), UK, with a thesis that introduced a novel approach to AI application in developing predictive models in the healthcare domain and marked a significant contribution in the field. Dr. Alfayez’s expertise lies in leveraging cutting-edge AI algorithms for big data analysis. Her innovative work has been published in esteemed peer-reviewed journals, showcasing her dedication to pushing the boundaries of AI applications in healthcare. With a bachelor’s degree in Computer Science and a master’s degree in Health Informatics, along with a decade of experience in the technology field, Dr. Alfayez brings a wealth of knowledge to her research pursuits. She is committed to developing novel prediction models to early predict the risk of events. Dr. Alfayez’s passion lies in bridging the gap between AI technology and different fields, including healthcare. Her extensive academic and professional background positions her as a leading expert in the application of AI.

Dr. Fawzi is a board-certified neurologist and epileptologist with expertise in clinical epidemiology and neurophysiology. He holds key positions at the King Faisal Specialist Hospital and Research Center in Jeddah, Saudi Arabia. Dr. Fawi focuses on integrating machine learning and artificial intelligence into clinical practice. He is the Medical Director of the Clinical Neurophysiology Laboratory and Director of the Epilepsy and EEG Fellowship Program. Dr. Fawzi is committed to advancing neurology standards through research and education.

Dr. Bokhari is an associate research scientist at King Abdullah International Research Center (KAIMRC) and adjunct assistant professor at the College of Public Health and Health Informatics, King Saud bin Abdulaziz University for Health Sciences. He received his Ph.D. in computer science from Virginia Commonwealth University, USA in 2019.

His research interests include artificial intelligence in medical imaging and genomics. He has published several papers in top academic journals, such as Nature Medicine, and received funding from King Abdullah University of Science and Technology (KAUST). He also worked as a consultant at the KAUST Smart Health Initiative project. In addition to his research, Dr. Bokhari is passionate about digital health and healthcare delivery.

Dr. Bokhari is a highly accomplished researcher making significant contributions to the field of artificial intelligence in medicine. He is passionate about using AI to improve healthcare delivery and he is committed to making a positive impact to improve healthcare.

Dr.Nasser Alqahtani works for Roche Pharma – Saudi Arabia as a country medical director. In his 17 years journey with the government, his precedent role was with the first Central Health Cluster – Ministry Of Health (MOH) as an executive director for drug and pharmaceutical affairs and an acting executive director for population health management directorate.

He is one of the Alfaisal University’s faculty members and works as an adjunct assistant professor of pharmacoepidemiology and Pharmacoeconomics

He used to serve as a director for drug safety and risk management deAdd Newpt at Saudi Food and Drug Authority (SFDA) for 13 consecutive years.

He receives his B.S. in Pharmacy from King Saud University, M.Sc. in clinical pharmacy from the UCL – UK and Ph.D. in pharmaceutical policy and outcomes research (Major: Pharmacoepidemiology) from Auburn University – Alabama, USA. He holds a certificate of higher diploma in pharmacovigilance and pharmacoepidemiology from London School of Hygiene and Tropical Medicine (LSHTM).

He is a member of a couple of professional societies. Besides, he used to chair the national evidence-based practice committee at Saudi Health Council (SHC).

He is a reviewer for a number of peer-reviewed journals and he used to chair the scientific committee of the SFDA’s research center, and acts as a senior research associate for the medication safety research chair-KSU. Dr. Alqahtani is a research collaborator with the Observational Health Data Sciences and Informatics (OHDSI) organization housed by Columbia University – New York, USA

His area of research focuses on the development and application of epidemiologic and statistical methods for evaluating the safety of medical products in large healthcare databases.

Dr. Jahad Alghamdi currently holds the position of Executive Director of Benefit and Risk Evaluation at the Saudi Food & Drug Authority. In this role, he oversees activities that focus on assessing the safety and effectiveness of medicinal products, as well as regulatory approval for clinical trials.

Throughout his career, Dr. Alghamdi has made noteworthy contributions to the scientific community. His commitment and expertise have led to the publication of numerous peer-reviewed articles in esteemed journals, solidifying his reputation as a respected authority in his field. Additionally, he has authored a book chapter, sharing his insights and knowledge with fellow professionals.

Prior to his current position, Dr. Alghamdi served as the Head of the Saudi Biobank at King Abdullah International Research Center. In this role, he was responsible for establishing and managing a crucial resource for medical research, facilitating groundbreaking studies and enabling advancements in precision medicine.

Dr. Yasser Kazzaz received his medical degree from King Saud University in 2007, his training in pediatrics and pediatric critical care fellowship at McGill University in 2014. He then completed an advanced critical care and ECMO fellowship The Hospital for Sick Children (SickKids). He obtained masters of public health in health systems and quality management in 2020 at (KSAU-HS).He is currently appointed as program director, pediatric intensive care physician, and associate professor of Pediatric Critical Care at (KSAU-HS).Dr. Kazzaz current research interest is focused on improving quality of care in pediatrics critical care through quality improvement projects and simulation with a specific interest in extracorporeal life support, sepsis, and organ donation.

Dr. Yaseen Arabi obtained his Internal Medicine Training then he was the Chief Medical Resident at Wayne State University, Detroit, MI, USA (1992-1995). He obtained pulmonary and critical care training at the University of Wisconsin, Madison, WI, USA (1995-1998). He is currently the Chairman of the Intensive Care Department, the Medical Director, Respiratory Services and Professor, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center.

He is currently the principal investigator/co-investigator on several multicenter randomized controlled trials. He has been involved in MERS and COVID-19 research. He has >450 publications including articles in leading medical journals. He is currently a Section Editor for Intensive Care Medicine on the Editorial Boards of several journals.

He received multiple grants and awards including the Barry A. Shapiro Memorial Award for Excellence in Critical Care Management, Society of Critical Care Medicine, USA (2011).

Mr. Kunal Sampat is hosted a podcast on clinical trials. The goal is to share with you thoughtful conversations on a wide range of clinical trial topics. Aside from the podcast, he is currently serve as the Interim Director of the Medical Product Development Management (MPDM) program at San Jose State University. He has also led over two dozen clinical trials projects which have included clinical trials at Abbott (vascular), Dexcom (diabetic care), and Ceribell (neurology). In his free time, he loves raising backyard chickens, reading, and connecting like-minded people with each other.

Dr. Kevin Zinchuk obtained his PharmD from Massachusetts College of Pharmacy and Health Sciences in 2011, joined the Brigham and Women’s Hospital Investigational Drug Services (IDS) department the same year and in 2020 was promoted to department manager. In his time in IDS, Kevin has overseen the implementation of electronic investigational drug orders, construction of a medication carousel and hazardous drug storage suite, and expansion of the staff from 10 to 15 FTEs, including establishment of a specialized residency training program.

Chairman, CEO, and Founder of CTI Clinical Trial and Consulting has more than 35 years of clinical, academic, and industry experience in global drug and device development programs. CTI, founded in 1999, is one of the top 20 largest contract research organizations (CROs) headquartered in Covington, KY with associates in North America, Europe, Latin America, Middle East / Africa, and Asia-Pacific. Our team has supported more than 175 drug and device approvals, and currently works on behalf of more than 300 global pharmaceutical and biotechnology companies.

Dr. Sara Bristol Calvert is the Director of Projects at the Clinical Trials Transformation Initiative where she provides senior operational leadership and develops and implements strategies to enhance the performance and capabilities of the project teams. Dr. Bristol Calvert has 20+ years of research experience. At CTTI, she has managed projects on the use of a single institutional review board, registry trials, diversity in clinical trials, and others. She also managed a multi-national observational study on the risk factors for hospital-acquired/ventilator associated pneumonia. Prior to joining CTTI, Dr. Bristol Calvert was a clinical pharmacist and project leader at the Duke Clinical Research Institute. Dr. Bristol Calvert received her Doctor of Pharmacy degree from the University of Pittsburgh and completed a primary care pharmacy residency at Duke University Medical Center and Health System.

Dr. Jens Samol is a Senior Consultant in Medical Oncology at Tan Tock Seng Hospital (TTSH) in Singapore. Dr Samol received his medical degree from the Free University of Berlin, Germany, and is a specialist in Internal Medicine, Haematology/Oncology, and Medical Oncology.Dr. Samol treats patients with all types of solid cancers and lymphoid neoplasms and has a particular interest in Thoracic Cancers, Head & Neck Cancers, Gastrointestinal Cancers (including HIPEC), Sarcoma, and Lymphoma.Dr. Samol is the Clinical Lead for Thoracic Cancers, Lymphoma (within Medical Oncology) and Sarcoma as well as the Clinical Lead for Genetic Counselling and Clinical Cancer Genetics & Genomics Service at TTSH.Dr. Samol is the Director for Clinical Trials (CRIO), Co-Director (TTSH) for P.H.Feng Research Centre and is the Clinical Research Lead of the Medical Oncology Department at TTSH.Dr. Samol holds a faculty appointment as an Assistant Professor at Lee Kong Chian School of Medicine, Singapore, as well as an Assistant Professor of Oncology at Johns Hopkins University School of Medicine, Baltimore, USA.

Dr.Barış Erdoğan is the CEO of Clinerion, a global RWD company. He studied computer engineering and holds M.Sc. and Ph.D. in technology. Over the last 25+ years of his professional experience, he practiced data mining techniques in various sectors. His last 15 years of professional experience in healthcare include the leadership of innovative Medical Informatics and Digital Transformation projects, and the implementation of end-to-end Healthcare IT enterprise information systems, both in the public and private sectors.

Dr. Katarzyna Moscicka is the global head of the Feasibility Department at PSI-CRO. A pharmacist by training, she has been responsible for global strategic feasibility and site ID for the past 15 years. Kasia has lead the development of PSI’s strategic feasibility methodology and processes, while also continuing to strengthen hands-on interaction with site partners. The site relationships that have been cultivated under Kasia’s leadership, helps teams to identify top ranking countries and sites that are tailored for each study.

Dr. Stephen Lockhart qualified in Medicine at Oxford in 1980.  After working around the UK in hospital medicine and research, I joined the pharmaceutical industry in 1986.  For over 30 years I have been engaged in global vaccine clinical R&D across all phases, most recently within Pfizer.  I was involved with bringing some major vaccines to the clinic, including pneumococcal and meningococcal conjugate vaccines and a modRNA COVID-19 vaccine, but have also learnt much from less successful developments.

Mr. Max Rashed is the CEO of Central & Eastern Europe Research Institute, CEERI and Avicenna Central of Medical Research, AVICEMER; a leading research companies operating in more than 20 countries in CEE and MENA regions. Mr. Rashed manages business opportunities by pharmaceutical and institutional sponsors and leads business development projects from initiation to implementation. He reviews operational plans and budgets. Mr. Rashed has successfully managed over 300 clinical research projects worldwide.

Mr. Rashed brings extensive experience in operations, financial and asset management working for top Fortune 500 companies. Mr. Rashed held executive leadership positions in the drug development industry, managing several aspects of clinical research at global levels, interfacing with sponsors, medical centers, labs & governmental drug agencies. During his career, he assisted in managing operations that had annual budgets that exceeded $8 billion. His background includes operations and logistics across the value stream map and leadership roles across a wide range of business activities. Mr. Rashed completed an Executive Masters of Business Administration from Michigan State University in 2000.

Dr. Mark McClellan,PHD is Director and Robert J. Margolis, M.D., Professor of Business, Medicine and Policy at the Duke-Margolis Institute for Health Policy at Duke University. He is a physician-economist who focuses on quality and value in health care, including payment reform, real-world evidence and more effective drug and device innovation. Mark is a former administrator of the Centers for Medicare & Medicaid Services and former commissioner of the U.S. Food and Drug Administration, where he developed and implemented major reforms in health policy. Dr. McClellan is an independent board member on the boards of Johnson & Johnson, Cigna, Alignment Healthcare, and PrognomIQ; co-chairs the Guiding Committee for the Health Care Payment Learning and Action Network; and serves as an advisor for Arsenal Capital Group, Blackstone Life Sciences.

As a legal consultant, thought leader and entrepreneur deeply immersed in the global clinical trial industry for over 25 years, she brings a wealth of distinguished experience. Myrthe is recognized for her expertise in navigating complexities and consistently delivering impactful solutions in this dynamic field. Throughout her career, she has undertaken influential roles at well-known CROs, including but not limited to Parexel and PharmaNet (now part of Syneos), acquiring a distinctive blend of legal acumen and practical industry knowledge. In 2010, she founded Salvius Legal, comprising a world-class team specialized in all aspects of clinical trial agreements and GDPR compliance. Her unwavering commitment to delivering high-quality contract management and legal consultancy services has not only garnered the trust of clients but also involved training C-Level executives and providing strategic guidance to pivotal stakeholders in clinical research. Additionally, she holds board memberships and affiliations with various international entities.

Dr. Shayan Bashir,  a Clinical Research Associate (CRA) at ICON, the largest CRO in North America since January 2024, manages study sites with a focus on adherence to SOPs, ICG-GCP guidelines, and regulatory requirements. His prior roles include CRA at Premier Research, Clinical Research Manager at DermEdge Research, overseeing Phase II-IV studies, and Research Assistant at St. Michael’s Hospital & McMaster Children’s Hospital. Shayan is also dedicated to training future professionals, serving as Chair for Workforce Development at ACRP Canada Chapter. His diverse research background spans Musculoskeletal, Oncology, Dermatology, Endocrine, and Cardiovascular studies, making him a valuable speaker at the conference.

Dr. Kyle Holen as a medical oncologist, Kyle saw first hand the devastating effects that serious disease can have on patients and their families. This is why, after completing medical school, residency, and fellowship, he dedicated his life’s work to finding better therapies for those who desperately need them.  He started by conducting research, education, and patient care as an associate professor at the University of Wisconsin. He continued his mission by leading multiple clinical research teams at AbbVie, a bio pharmaceutical company.  Kyle is currently the head of development at Moderna, responsible for the clinical research programs in oncologic, rare, cardiovascular, pulmonary, and autoimmune diseases.

Dr. Eva Turgonyi is Medical Director for GCC at AstraZeneca, based in Dubai, UAE. She is a senior medical affairs leader, a physician, committed to improving health outcomes in multiple therapeutic areas, advancing clinical practice change with science driven and patient focused approaches. She has led multiple medical evidence generation programs including global phase III studies and international disease registries. Her work focuses on pioneering innovative health solutions, shaping health policies, improving health equity and fostering collaborations across the healthcare ecosystem.

Dr. Vladimir Misik, MSC. PhD., is a renowned scientist and Fogarty Fellow at the National Cancer Institute NIH, with extensive experience as a research scientist at the George Washington University and the Slovak Academy of Sciences. He has held pivotal roles in pharmaceutical product development, including VP and Head of Global Operations Center at Quintiles (IQVIA). As an entrepreneur, he is a Partner/Co-founder of VIARES Academy and the Founder of LongTaal, a clinical trial informatics company. With a research focus on the globalization of industry clinical trials, Mr. Misik has authored over 60 articles and holds leadership positions in global committees for clinical research and diversity and inclusion.

Dr. SeungHwan Lee is an Associate Professor of Department of Clinical Pharmacology and Therapeutics and the Head of Quality Improvement Office of Clinical Trials Center at Seoul National University Hospital, Seoul, Korea. He received his Ph.D. degree in clinical pharmacology in 2012 from Seoul National University College of Medicine. In recent years, Dr. Lee annually has been participating in around twenty clinical trials including first-in-human studies as a principal investigator and has tried to develop or adopt innovative clinical trial technologies through his clinical studies.

Dr.Mohamed Mostafa, CEO  and board member of PDC-CRO, leads a dedicated team supporting Pharmaceuticals, Biotech companies, and Research Institutions in clinical development and transformative research. With his vast experience; Mohamed has expanded research capabilities and infrastructure, focusing on improving patient outcomes. Under his leadership, PDC has emerged as a premier CRO in the MEA, specializing in early-stage clinical development, trial management, and regulatory services. Mohamed oversees the organization’s strategic initiatives.Throughout his career, Mohamed has fostered collaborations with local and international partners and worked closely with regulatory agencies to implement strategic plans aligned with regional guidelines.

Dr.Naeem Noordin, CEO of Siara Limited, a specialised clinical research consultancy and training organisation with offices in the UK (Siara Limited) and UAE (Siara Consultancy FZ-LLC).     Naeem brings over 25 years of global experience in clinical research and biopharmaceutical education and is experienced in both the Pharmaceutical and Contract Research Organisation industry.  Naeem has lived and worked in Europe, US, Middle East and Asia.  Naeem’s professional odyssey has been marked by his role as a GCP consultant, advisor and trainer, where his expertise bridged critical knowledge voids within the realm of clinical research. His hands-on experience and comprehensive understanding of research methodologies have become invaluable assets in training the next generation of researchers and professionals.  Naeem’s passion for clinical research and education led to establish his company Siara in the UK in 2013 and the UAE in 2023.  Naeem currently resides between the UK and UAE.

Dr.Pawel Orlowski, MD. Working in the capacity of a Sr Director Clinical Operations at a CRO and an Operations Director at a Site Enabling Organization. Active management roles in a CRO and a SEO allow me to understand the operational challenges of clinical trials from the perspective of a CRO and a medical site. This is a great advantage since theoretical study considerations at the CRO end need to be in line with routine medical practice in order for a given study to be feasible for the medical site team. My operational awareness of how regular medical care is organized at a site level, allows me to prevent most possible operational problems still at the stage of study setup in a given region.

Dr. Assem is a strategic senior executive with 30+ years of experience in life sciences. He has held diverse roles in pharmaceutical, biotech, and CRO industries. Currently, Managing Director of CTI EMEA, he has a strong track record in clinical research, regulatory affairs, and business development. Dr. Assem has successfully led teams, ensured top and bottom-line growth, and introduced innovative products in the ME region. With a physician background and an MBA from Maastricht School of Business, he brings a deep understanding of the industry and strong network of contacts.

Dr.Sahar Ebrahim,MD is a Public Health Physician with 25+ years of experience in the pharmaceutical industry. Currently serving as Head of IQVIA Clinical Research Operations in MENA and Managing Director of IQVIA RDS Egypt LLC. Expertise in diverse therapeutic areas and building successful teams. Extensive involvement in establishing Quintiles’ presence in MENA. Strong collaboration with regulatory bodies and track record of delivering projects with high quality. Skilled in vendor qualification, strategic partnerships, and establishing research units.